Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Putative metabolites that met the criteria for receiver operating characteristic curve analysis. No. | MedianM/Z | Median retention time (minute) | Ionization mode | Putative metabolite | METLIN ID | Chemical Formular | Ion adducts | Mass error (ppm) | S. mansoni | S. japonicum | S. mekongi | ROC-AUC | p-value | FC | ROC-AUC | p-value | FC | ROC-AUC | p-value | FC: 4. | 455.3511 | 12.81 | Negative | 1α-hydroxy-2β-(3-hydroxypropoxy) vitamin D3 | 42398 | C27H44O4 | M-H2O-H | 3 | 0.94 | 0.008 | -4.54 | 1 | 0.001 | -8.74 | 1 | 0.016 | -5.36
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Animal research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics
Study design awaiting verification · PLOS Neglected Tropical Diseases · 2024
Original publication title
Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics
© 2024 Chienwichai et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Schistosomiasis is one of the most devastating human diseases worldwide. The disease is caused by six species of Schistosoma blood fluke; five of which cause intestinal granulomatous inflammation and bleeding. The current diagnostic method is inaccurate and delayed, hence, biomarker identification using metabolomics has been applied. However, previous studies only investigated infection caused by one Schistosoma spp., leaving a gap in the use of biomarkers for other species. No study focused on understanding the progression of intestinal disease. Therefore, we aimed to identify early gut biomarkers of infection with three Schistosoma spp. and progression of intestinal pathology.
We infected 3 groups of mice, 3 mice each, with Schistosoma mansoni, Schistosoma japonicum or Schistosoma mekongi and collected their feces before and 1, 2, 4 and 8 weeks after infection. Metabolites in feces were extracted and identified using mass spectrometer-based metabolomics. Metabolites were annotated and analyzed with XCMS bioinformatics tool and Metaboanalyst platform. From >36,000 features in all conditions, multivariate analysis found a distinct pattern at each time point for all species. Pathway analysis reported alteration of several lipid metabolism pathways as infection progressed.
Disturbance of the glycosaminoglycan degradation pathway was found with the presence of parasite eggs, indicating involvement of this pathway in disease progression. Biomarkers were discovered using a combination of variable importance for projection score cut-off and receiver operating characteristic curve analysis. Five molecules met our criteria and were present in all three species: 25-hydroxyvitamin D2, 1α-hydroxy-2β-(3-hydroxypropoxy) vitamin D3, Ganoderic acid Md, unidentified feature with m/z 455.3483, and unidentified feature with m/z 456.3516. These molecules were proposed as trans-genus biomarkers of early schistosomiasis.
Our findings provide evidence for disease progression in intestinal schistosomiasis and potential biomarkers, which could be beneficial for early detection of this disease.
Author summary
Schistosomiasis is a parasitic disease caused by the blood fluke Schistosoma. Five species of Schistosoma cause intestinal damage and inflammation, but the current method of diagnosis is not satisfactory because it lacks sensitivity and timeliness. Therefore, we applied metabolomics to identify the overall types and abundance of compounds in biological samples to discover new markers. Previous metabolomic studies focused only on infection with one species, making it difficult to detect disease caused by other species. Moreover, no study examined progression of intestinal disease.
In this study, we used a mouse model and metabolomics to investigate changes in the gut environment from the early stage of the disease and identify markers of early infection caused by three different species of Schistosoma. We found that changes in compounds related to lipid metabolism since early infection and some pathways, such as glycosaminoglycan degradation, might be related to intestinal disease. We identified five compounds as early biomarkers of schistosomiasis, which were shared among the three species.
These compounds could be used for future biomarker development, which could facilitate diagnosis of schistosomiasis.
Authors’ abstract
Schistosomiasis is one of the most devastating human diseases worldwide. The disease is caused by six species of Schistosoma blood fluke; five of which cause intestinal granulomatous inflammation and bleeding. The current diagnostic method is inaccurate and delayed, hence, biomarker identification using metabolomics has been applied. However, previous studies only investigated infection caused by one Schistosoma spp., leaving a gap in the use of biomarkers for other species. No study focused on understanding the progression of intestinal disease. Therefore, we aimed to identify early gut biomarkers of infection with three Schistosoma spp. and progression of intestinal pathology.
We infected 3 groups of mice, 3 mice each, with Schistosoma mansoni, Schistosoma japonicum or Schistosoma mekongi and collected their feces before and 1, 2, 4 and 8 weeks after infection. Metabolites in feces were extracted and identified using mass spectrometer-based metabolomics. Metabolites were annotated and analyzed with XCMS bioinformatics tool and Metaboanalyst platform. From >36,000 features in all conditions, multivariate analysis found a distinct pattern at each time point for all species. Pathway analysis reported alteration of several lipid metabolism pathways as infection progressed.
Disturbance of the glycosaminoglycan degradation pathway was found with the presence of parasite eggs, indicating involvement of this pathway in disease progression. Biomarkers were discovered using a combination of variable importance for projection score cut-off and receiver operating characteristic curve analysis. Five molecules met our criteria and were present in all three species: 25-hydroxyvitamin D2, 1α-hydroxy-2β-(3-hydroxypropoxy) vitamin D3, Ganoderic acid Md, unidentified feature with m/z 455.3483, and unidentified feature with m/z 456.3516. These molecules were proposed as trans-genus biomarkers of early schistosomiasis.
Our findings provide evidence for disease progression in intestinal schistosomiasis and potential biomarkers, which could be beneficial for early detection of this disease.
Author summary
Schistosomiasis is a parasitic disease caused by the blood fluke Schistosoma. Five species of Schistosoma cause intestinal damage and inflammation, but the current method of diagnosis is not satisfactory because it lacks sensitivity and timeliness. Therefore, we applied metabolomics to identify the overall types and abundance of compounds in biological samples to discover new markers. Previous metabolomic studies focused only on infection with one species, making it difficult to detect disease caused by other species. Moreover, no study examined progression of intestinal disease.
In this study, we used a mouse model and metabolomics to investigate changes in the gut environment from the early stage of the disease and identify markers of early infection caused by three different species of Schistosoma. We found that changes in compounds related to lipid metabolism since early infection and some pathways, such as glycosaminoglycan degradation, might be related to intestinal disease. We identified five compounds as early biomarkers of schistosomiasis, which were shared among the three species.
These compounds could be used for future biomarker development, which could facilitate diagnosis of schistosomiasis.
Publication and source details
Original title: Identification of trans-genus biomarkers for early diagnosis of intestinal schistosomiasis and progression of gut pathology in a mouse model using metabolomics
Peerut Chienwichai; Phornpimon Tipthara; Joel Tarning; Yanin Limpanont; Phiraphol Chusongsang; Yupa Chusongsang; Nuttapohn Kiangkoo; Poom Adisakwattana; Onrapak Reamtong
PLOS Neglected Tropical Diseases · 2024
The authors have declared that no competing interests exist.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:07:46.996222+00:00
DOI: 10.1371/journal.pntd.0011966 · PMC10880994